文献速递认知障碍与痴呆

典型与非典型阿尔茨海默病表型的生存差异

Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.
PubMed 文献 · Neurology · 2025-04-28

该回顾性队列研究基于阿姆斯特丹痴呆队列,纳入2081例生物标志物确诊的散发性AD患者,比较典型AD(n=1801)与非典型AD(n=280,含PCA、lvPPA、bvAD)的生存期。非典型AD中位生存期6.3年(95%CI 5.8-6.9),短于典型AD的7.2年(95%CI 7.0-7.5),p=0.02;校正年龄、性别、教育、MMSE和APOEε4后,非典型AD死亡风险增加31%(HR=1.31,95%CI 1.10-1.56,p=0.002)。

要点

  • 非典型AD中位生存期6.3年,短于典型AD的7.2年(p=0.02)。
  • 校正混杂因素后,非典型AD死亡风险较典型AD增加31%(HR=1.31)。
  • PCA亚型死亡风险显著升高(HR=1.35,95%CI 1.05-1.73,p=0.019)。

核心结论

  • 非典型AD(PCA、lvPPA、bvAD)的生存期较典型AD缩短,且在校正年龄、性别、教育、APOEε4携带和疾病严重程度后,非典型AD仍与死亡率增加相关。

研究设计与样本

  • 回顾性队列研究,从阿姆斯特丹痴呆队列中选取生物标志物确诊的散发性AD患者,处于轻度认知障碍或痴呆阶段,分为非典型AD表型(PCA、lvPPA、bvAD;多学科共识和回顾性病例发现)和典型AD参考组。

主要发现

  • 共纳入2081例患者(年龄65±8岁,52%女性),典型AD 1801例,非典型AD 280例(PCA 112例、lvPPA 86例、bvAD 82例)。
  • 非典型AD中位生存期6.3年(95%CI 5.8-6.9),典型AD为7.2年(95%CI 7.0-7.5),p=0.02。
  • 各非典型AD亚型中位生存期分别为PCA 6.3年(95%CI 5.5-7.3,p=0.055)、lvPPA 6.6年(95%CI 5.7-7.7,p=0.110)、bvAD 6.3年(95%CI 5.0-9.1,p=0.121,48%死亡),均较典型AD短但无统计学显著性。
  • 模型2纳入非典型AD后模型拟合改善(χ2=8.88,p=0.003),非典型AD与死亡风险增加31%相关(HR=1.31,95%CI 1.10-1.56,p=0.002)。
  • 模型3中各亚型贡献:PCA的HR=1.35(95%CI 1.05-1.73,p=0.019);lvPPA的HR=1.27(95%CI 0.94-1.69,p=0.114);bvAD的HR=1.31(95%CI 0.94-1.83,p=0.105)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Survival estimates for individuals with Alzheimer disease (AD) are informative to understand the disease trajectory, but precise estimates for atypical AD variants are scarce. Atypical AD variants are characterized by nonamnestic phenotypes, an early onset, and lower prevalence of APOEε4 carriership, which affect the AD trajectory. We aimed to provide survival estimates for posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia (lvPPA), and behavioral AD (bvAD) and to evaluate the effect of these atypical AD diagnoses beyond known mortality determinants. METHODS: From the Amsterdam Dementia Cohort, we retrospectively selected patients with biomarker-confirmed sporadic AD presenting at the memory clinic in the mild cognitive impairment or dementia stage. Patients were classified into atypical AD phenotypes (PCA, lvPPA, bvAD; multidisciplinary consensus and retrospective case finding) and a typical AD reference group (excluding unclassifiable atypical presentations or unconfirmed future AD dementia). Survival estimates from the first visit to death/censoring (Central Public Administration) were determined (Kaplan-Meier analysis) and compared (log-rank tests) across diagnostic groups. To assess associations of atypical AD with mortality, Cox proportional hazard models were constructed including age, sex, education, MMSE score, and APOEε4 carriership (model 1), followed by adding the atypical AD group (model 2) or atypical AD variants (model 3). A likelihood ratio test was performed to compare the fit of model 1 and model 2. RESULTS: A total of 2,081 patients (aged 65 ± 8 years, 52% female) were classified as typical AD (n = 1,801) or atypical AD (n = 280; PCA [n = 112], lvPPA [n = 86], and bvAD [n = 82]). The estimated median survival time for atypical AD of 6.3 years (95% CI [5.8-6.9]) was shorter than for typical AD (7.2 [7.0-7.5], p = 0.02). Median survival durations across the atypical AD variants were consistently, albeit nonsignificantly, shorter (PCA: 6.3 [5.5-7.3], p = 0.055; lvPPA: 6.6 [5.7-7.7], p = 0.110; bvAD: 6.3 [5.0-9.1], p = 0.121, 48% deceased). Including atypical AD improved the model fit (model 2; χ2 = 8.88, p = 0.003) and was associated with 31% increased mortality risk compared with typical AD (hazard ratio [HR] = 1.31 [1.10-1.56], p = 0.002). In model 3, contributions of the variants were as follows: HRPCA = 1.35 (1.05-1.73), p = 0.019; HRlvPPA = 1.27 (0.94-1.69), p = 0.114; HRbvAD = 1.31 (0.94-1.83), p = 0.105. DISCUSSION: Survival in atypical AD (PCA, lvPPA, bvAD) was shorter compared with typical AD. These atypical variants are associated with increased mortality beyond age, sex, education, APOEε4 carriership, and disease severity. Future studies are required to address generalizability of these findings and to identify factors that explain the observed survival differences.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bader I, Groot C, Van Der Flier WM, et al. Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease. Neurology. 2025. PMID: 40294367. doi:10.1212/WNL.0000000000213603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。